Ironwood Pharmaceuticals (IRWD) Q2 2026 earnings — TrendMatrix coverage

Adjusted EPS

$0.31

Estimate

$0.28

Surprise

+12.7%

Revenue (period 2026-06-30)

$113.0M

Score at report (before → after)

7.3 → 7.0/10

Revenue source: xbrl.

Ironwood Pharmaceuticals (IRWD) beat the $0.28 estimate with adjusted EPS of $0.31 — a large 12.7% upside surprise. TrendMatrix's engine moved from Buy (Wait) (7.3/10) to Strong Buy at 7.0/10 after the report — the engine's score fell despite the beat.

TrendMatrix currently rates IRWD Buy (Wait) at 7.3/10.

2 of the last 4 quarters beat the estimate; this quarter's +12.7% surprise compares with a -26.2% four-quarter average. Next scheduled report: 2026-11-09.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$3.63

Entry target

$3.45

Price target

$5.18

Stop

$3.21

Upside to target

+42.7%

Reward-to-risk

4.0:1

Model outputs from TrendMatrix’s engine as of 2026-10-07 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Drug Manufacturers - Specialty & Generic

Market cap

$599.8M

P/E (fwd)

2.4

P/E (ttm)

4.7

52-week range

$1.41–$5.78

Off 52-week high

37.2%

RSI (14)

30

Volume vs avg

0.86×

Score today

7.3/10